The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
Open accessAbstract
Objectives We report 2-year results from CheckMate 141 to establish the long-term efficacy and safety profile of nivolumab and outcomes by tumor PD-L1 expression in patients with recurrent or metastatic (R/M),platinum-refractory squamous cell carcinoma of the head and neck (SCCHN). Methods Patients with R/M SCCHN with tumor progression/recurrence within 6 months of platinum therapy were randomized 2:1 to nivolumab 3 mg/kg every 2 weeks or investigator’s choice (IC). Primary endpoint: overall survival (OS). Data cutoff: September 2017. Results With 24.2 months’ minimum follow-up, nivolumab (n =240) continued to improve OS vs IC (n = 121), hazard ratio (HR) = 0.68 (95% CI 0.54–0.86). Nivolumab nearly tripled the estimated 24-month OS rate (16.9%) vs IC (6.0%), and demonstrated OS benefit across patients with tumor PD-L1 expression ≥1% (HR [95% CI] = 0.55 [0.39–0.78]) and < 1% (HR [95% CI] =0.73 [0.49–1.09]), and regardless of tumor HPV status. Estimated OS rates at 18, 24, and 30 months with nivolumab were consistent irrespective of PD-L1 expression (< 1%/≥1%). In the nivolumab arm, there were no observed differences in baseline characteristics or safety profile between long-term survivors and the overall population. Grade 3–4 treatment-related adverse event rates were 15.3% and 36.9% for nivolumab and IC, respectively. Conclusion Nivolumab significantly improved OS at the primary analysis and demonstrated prolonged OS benefit vs IC and maintenance of a manageable and consistent safety profile with 2-year follow-up. OS benefit was observed with nivolumab irrespective of PD-L1 expression and HPV status. (Clinicaltrials.gov: NCT02105636)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Self-citationEpidemiologic Trends in Head and Neck Cancer and Aids in Diagnosis
Vigneswaran, N., & Williams, M. D. (2014) · Oral and Maxillofacial Surgery Clinics of North America · doi:10.1016/j.coms.2014.01.001 · Cited by 815
Harrington, K. J., Ferris, R. L., Blumenschein, G., Colevas, A. D., Fayette, J., Licitra, L., Kasper, S., Even, C., Vokes, E. E., Worden, F., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30421-7 · Cited by 428
Self-citationThe Humanistic Burden of Head and Neck Cancer: A Systematic Literature Review
Wissinger, E., Griebsch, I., Lungershausen, J., Byrnes, M. J., Travers, K. U., & Pashos, C. L. (2014) · PharmacoEconomics · doi:10.1007/s40273-014-0199-x · Cited by 139
Saloura, V., Cohen, E. E. W., Licitra, L. F., Billan, S., Dinis, J., Lisby, S., & Gauler, T. C. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2459-z · Cited by 88
Self-citationThe role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment
Pai, S. I., Zandberg, D. P., & Strome, S. E. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2016.08.001 · Cited by 70
Research works printed but not linked: 3
- Bernier, 2008, Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck, Nat Clin Pract Oncol, 5, 705, 10.1038/ncponc1228 · doi:10.1038/ncponc1228
- Gillison, 2017, J Clin Oncol, 35, 6019, 10.1200/JCO.2017.35.15_suppl.6019 · doi:10.1200/jco.2017.35.15_suppl.6019
- Haddad, 2017, Treatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck(SCCHN) in the phase 3 CheckMate 141 study: a biomarker analysis and updated clinical outcomes [abstract], Ann Oncol, 28, 1043O
Cited by
Burtness, B., Harrington, K. J., Greil, R., Soulières, D., Tahara, M., de Castro, G., Psyrri, A., Basté, N., Neupane, P., Bratland, Å., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32591-7 · Cited by 3,336
Self-citationChow, L. Q. M. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1715715 · Cited by 2,075
Mody, M. D., Rocco, J. W., Yom, S. S., Haddad, R. I., & Saba, N. F. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01550-6 · Cited by 847
Self-citationCohen, E. E. W., Bell, R. B., Bifulco, C. B., Burtness, B., Gillison, M. L., Harrington, K. J., Le, Q.-T., Lee, N. Y., Leidner, R., Lewis, R. L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0662-5 · Cited by 722
Self-citationImmune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
Cillo, A. R., Kürten, C. H. L., Tabib, T., Qi, Z., Onkar, S., Wang, T., Liu, A., Duvvuri, U., Kim, S., Soose, R. J., et al. (2020) · Immunity · doi:10.1016/j.immuni.2019.11.014 · Cited by 668
Self-citation
Metadata
- Authors
- Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K. J., Kasper, S., Vokes, E. E., Even, C., Worden, F., Saba, N. F., Docampo, L. C. I., Haddad, R., Rordorf, T., Kiyota, N., Tahara, M., Lynch, M., Jayaprakash, V., Li, L., & Gillison, M. L.
- Venue
- Oral Oncology
- Publisher
- Elsevier BV
- Published
- 2018-06
- Volume
- 81
- Pages
- 45-51
- ISSN
- 1368-8375 (ISSN-L)
- OpenAlex
- W2799372507
- Cited by
- 804
- References
- 8
- FWCI
- 31.76
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Funders
- Bristol-Myers Squibb
- Ono Pharmaceutical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. https://app.cochat.ai/papers/10.1016/j.oraloncology.2018.04.008
- The paper
- Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K. J., Kasper, S., Vokes, E. E., Even, C., Worden, F., Saba, N. F., Docampo, L. C. I., Haddad, R., Rordorf, T., Kiyota, N., Tahara, M., Lynch, M., Jayaprakash, V., . . . Gillison, M. L. (2018). Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncology. https://doi.org/10.1016/j.oraloncology.2018.04.008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.